Close X

Welcome to the Contingent Commitment Exchange

TERMINAL

Terminal is the live negotiation environment. Terminal access is restricted to approved users, to request access or you are having trouble logging in, contact support@pharmaccx.com.

SANDBOX

Sandbox is designed as a simulation environment which supports the full PharmaCCX platform functionality for training and practicing negotiations with no real world consequences. Reach out to info@pharmaccx.com to get a demo and sign up for access.

Close X

Helping you give more patients a chance to survive and thrive

With the Contingent Commitment Exchange, you can reach better agreements quicker and help more patients.

Negotiate

Set negotiation parameters in dimensions beyond just price and make a confidential set of "Contingent Commitments" to articulate what you'd be willing to do if the other parties agree.

Agree

Reach an agreement when the Exchange identifies a match. If there’s no match, a new round of negotiation starts.

Settle

When an agreement is reached, the deal becomes binding. The platform can then track the agreement and provide relevant insights.

Manage

Track and manage settled agreements, and leverage past experience to inform future agreements, negotiations and strategies.

Challenge

Payer A reimburses at 100 gold coins per QALY.

Asterix Pharma and Betafix Pharma are each in the market of extending the lives for a rare form of cancer for 1 year with no side effects. Clinical evidence shows that when their drugs are used together, they extend a patient's life by 1.5 years.

The combination cannot be priced with existing pricing dynamics.

Payer A

Is willing to pay 150 gold coins for 1.5 years life extension.

Asterix Pharma & Betafix Pharma

Are willing to accept a different price in combo provided it doesn’t reduce their price as a monotherapy. Due to anti-trust regulations they cannot communicate with each other.

Results

By making confidential contingent commitments on the CCX platform, Asterix Pharma and Betafix Pharma negotiate how to distribute their gold coins.

Asterix Pharma agrees to receive 80 gold coins, and Betafix agrees to receive 70 gold coins when their drugs are used in combo. CCX deal management allows the payer to automatically settle the agreement monthly without an increased administrative burden.

Challenge

AmazingDrug is in the market as a treatment for toenail cancer, for which it extends a patients life by one year and is reimbursed at 100 gold coins per QALY. Recent clinical trials show it also treats elbow cancer, but only extends a patient's life by 6 months.

At 100 gold coins per QALY, AmazingDrug is not getting to elbow cancer patients. Payer A and Asterix Pharma are both unhappy with this arrangement.

Payer A

Is willing to have a different price provided there isn’t a big administrative burden.

Asterfix Pharma

Is willing to accept a lower price for elbow cancer provided the terms and prices for elbow and toenail cancer are separately negotiated.

Results

By making confidential contingent commitments, Payer A and Asterfix Pharma agree on terms so patients of elbow cancer finally get their treatment.

Payer A reimburses Asterfix Pharma 60 gold coins for elbow cancer patients maintaining their 100 gold coin payment for toenail cancer. CCX deal management allows the payer to automatically settle the agreement monthly without an increased administrative burden.

Challenge

AwesomeDrug is a gene therapy that cures Old Age for some patients. For others, it has no effect.

The exact ratio is unknown.

Payer A does not want to pay for AwesomeDrug given only some percentage of patients receive the value

Payer A

Is willing to pay full price for whenever it actually cures a patient of old age.

Asterfix Pharma

Is willing to rebate the payer 100% for when the drug doesn’t work, provided they get paid when it does work.

Results

Asterfix Pharma is able to upload its patient data into the CCX platform and Payer A receives a rebate whenever AwesomeDrug does not work. CCX deal management platform processes the data and communicates to Asterfix Pharma and Payer A quarterly on the rebates owed between them.

Challenge

Payer A has 20 deals they are currently managing manually.

They don’t have the administrative capacity to enter into more agreements, but they see the need for 20 additional impactful Managed Entry Agreements (MEA).

Payer A

Is willing to do more deals if they had the time and resources to do so.

Results

Payer A uploads their 20 existing deals to the CCX deal management platform to quickly and efficiently administer them, providing their team with the capacity to enter into the 20 additional Managed Entry Agreements that also go onto the CCX deal management platform.

How you can get your next deal done

Negotiation Phase

Make Contingent Commitments

Define the terms you’ll agree to to bring a complex therapy to market, like reserve prices, price volume rebates, performance- or outcome-based provisions, and more

Communicate without Revealing

Negotiate with the relevant parties revealing information to the platform, but not to the counterparts. The platform allows you to keep proprietary information and your negotiation position hidden unless a deal is reached. In cases where it applies it also helps with complex anti-trust regulations that limit communication.

Data-Driven Calculations

CCX imports and tracks data on specific therapies, like when it was used, what it was used for, how it was used, or any other agreed upon data fees that inform the tracking and execution of the agreement.

Stay on Budget

View all pending and settled agreements in one place to see how they are tracking against your budgets and projections.

Improve Deal Management

Manage all existing and pending agreements in one place, and get notifications when it’s time to renegotiate.

Post-Deal Phase

Benefits

Reach Fair Deals

Agreements satisfy the requirements and budgets of both pharma and payers—no preference is given to one involved party over another.

Improve More Patient Outcomes

Increase patient access to complex therapies with more outcome- and value-based contracts, combination and indication-based therapies, even deals you never thought were possible.

Be Transparent

Be upfront about what you want from an agreement before you actually start negotiations.

Remain Compliant

Remain compliant with Anti-Trust and Competition law which prohibits companies from discussing common price strategy.

Don't Sacrifice Privacy

Only share what you want, when you want. For example, set contingent commitments but remain private until a payer and/or other pharma company agrees to them.

Maximize Efficiency

Reduce the administrative burden associated with legacy negotiation and deal tracking processes—and get deals done in days, not months.

FAQ

Who initiates a deal on The Exchange?

What Contingent Commitments can be set?

Should I be concerned about agreements favoring one party over another?

What data does PharmaCCX have access to?

Schedule a demo